Dynamics of incidence with malignant neoplasms in the thyroid gland among Chelyabinsk region population over 1998–2016: Clynic and epidemiological characteristics [PDF]
Analiz Riska Zdorovʹû, 2019 The paper dwells on assessing dynamics of incidence with malignant neoplasms (MN) in the thyroid gland among Chelyabinsk region population over 1998–2016.
S.A. Shalaginov +3 more
doaj +2 more sources
Update from the 2022 World Health Organization Classification of Thyroid Tumors: A Standardized Diagnostic Approach [PDF]
Endocrinology and Metabolism, 2022 The fifth edition of the World Health Organization (WHO) histologic classification of thyroid neoplasms released in 2022 includes newly recognized tumor types, subtypes, and a grading system.
Chan Kwon Jung +2 more
doaj +1 more source
Diagnostic Utility of Immunohistochemistry Markers Galectin-3, CK19 and CD56 in Thyroid Neoplasms: A Descriptive Study [PDF]
Journal of Clinical and Diagnostic Research, 2022 Introduction: The spectrum of follicular patterned thyroid lesions vary from benign to malignant, their categorisation based solely on morphology can often be equivocal.
Jayasree Raman +2 more
doaj +1 more source
HBME-1 expression by thyroid neoplasms in a Nigerian tertiary health Centre
Ibom Medical Journal, 2023 Aim: The aim of this study is to review the histopathological diagnosis of thyroid neoplasms seen in OAUTHC Ile Ife using HBME-1 immunohistochemical marker. Materials and methods: We studied all thyroid neoplasms diagnosed in the Department of Morbid
Soremekun AI, Olaofe OO, Komolafe AO
doaj +1 more source
Concomitant bilateral papillary thyroid carcinoma and parathyroid adenoma
Case Reports in Clinical Practice, 2022 Thyroid malignant neoplasms are the most prevalent cancer of the endocrine system, and their concurrence with parathyroid neoplasms is extremely rare.
Reza Hajebi +2 more
doaj +1 more source
Updates in the Pathologic Classification of Thyroid Neoplasms: A Review of the World Health Organization Classification [PDF]
Endocrinology and Metabolism, 2020 Advances in medical sciences and evidence-based medicine have led to momentous changes in classification and management of thyroid neoplasms. Much progress has been made toward avoiding overdiagnosis and overtreatment of thyroid cancers.
Yanhua Bai +2 more
doaj +1 more source
Acta Medica Iranica, 2021 Thyroid malignancies are found in 7% to 15% of all thyroid nodules. Immunohistochemical markers, including CK19, HBME-1and TROP2, have shown an effective role in identifying these malignancies.
Masoud Mohebbi +4 more
doaj +1 more source
Galectin-3 Immunohistochemical Expression in Thyroid Neoplasms [PDF]
Journal of Clinical and Diagnostic Research, 2015 Background: Galectin-3 has been implicated in the regulation of cellular growth, differentiation and malignant transformation in various organs including thyroid gland. It has been extensively studied as an immunohistochemical (IHC) marker in thyroid
B S Sumana +2 more
doaj +1 more source
New biomarkers: prospect for diagnosis and monitoring of thyroid disease
Frontiers in Endocrinology, 2023 After the metabolic syndrome and its components, thyroid disorders represent the most common endocrine disorders, with increasing prevalence in the last two decades.
Mirjana T. Macvanin +7 more
doaj +1 more source
Diagnostic role of immunohistochemical markers CK19 and CD56 in thyroid neoplasms
MGM Journal of Medical Sciences, 2023 Introduction: Thyroid cancer is the most common type of endocrine cancer, with an increasing prevalence. The possibility of a malignant neoplasm is the primary concern in people with thyroid nodules. The presence of a plethora of variants complicates the
Pallavi Priyadarshini +2 more
doaj +1 more source